Epigenomics EBIT par action

Que fait Epigenomics ? Epigenomics AG develops and commercializes blood-based diagnostic products for cancer screening and diagnosis, primarily targeting colorectal and lung cancer. The company's main products are Epi proColon, a blood test for colorectal cancer screening, and Epi proLung, a blood test for detecting lung cancer in blood plasma. These products are sold to healthcare providers and laboratories in Europe and the United States, where the company operates its commercial activities. The firm also generates revenue from services related to research, product development, regulatory approval, and manufacturing of in-vitro diagnostic (IVD) products. Epigenomics AG's revenue streams are derived from the sale of Epi proColon and Epi proLung to medical institutions and diagnostic laboratories across its operational regions. The company's focus on blood-based diagnostics for cancer screening positions it within the molecular diagnostics sector, with a specific emphasis on non-invasive testing solutions. Its business model relies on the commercialization of proprietary diagnostic tests and associated services to healthcare providers and laboratories. The company's products are designed to support early cancer detection, with Epi proColon targeting colorectal cancer screening and Epi proLung addressing lung cancer detection. These tests are marketed to healthcare professionals and laboratories in Europe and the United States, where Epigenomics AG has established its commercial presence. The firm's service offerings include research, product development, regulatory support, and manufacturing for IVD products, which contribute to its overall revenue. Epigenomics est l'une des entreprises les plus populaires sur Eulerpool.